SCHEMBL8293259

SCHEMBL8293259

NCC[C@H]1C[C@@H](C(=O)CCc2ccccc2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.44
ALDH1A1 P00352 2/20 0.42
FFAR1 O14842 1/20 0.42
POLB P06746 1/20 0.41
TDP1 Q9NUW8 2/20 0.40
HDAC2 Q92769 2/20 0.40
HDAC8 Q9BY41 2/20 0.40
HDAC6 Q9UBN7 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
CYP2A6 P11509 1/20 0.40
HTR2A P28223 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.40
CYP2C19 P33261 1/20 0.40
NPC1 O15118 1/20 0.40
SIGMAR1 Q99720 1/20 0.39
HDAC1 Q13547 2/20 0.39
HDAC3 O15379 1/20 0.39
MAPK1 P28482 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27109144 0.77 KEAP1 (0.57) KEAP1ALDH1A1FFAR1POLBTDP1
SCHEMBL14036245 0.74 ALDH1A1 (0.56) KEAP1ALDH1A1FFAR1POLBTDP1
SCHEMBL15684283 0.74 S1PR1 (0.50) KEAP1POLBHDAC2HDAC8HDAC6
SCHEMBL5880795 0.74 ALDH1A1 (0.60) KEAP1ALDH1A1FFAR1POLBTDP1
SCHEMBL5007205 0.73 SIGMAR1 (0.49) POLBSIGMAR1MAPT
SCHEMBL5007207 0.73 SIGMAR1 (0.49) POLBSIGMAR1MAPT
SCHEMBL11880887 0.72 ALDH1A1 (0.63) KEAP1ALDH1A1FFAR1POLBTDP1
SCHEMBL9285630 0.70 KEAP1 (0.48) KEAP1ALDH1A1FFAR1POLBTDP1
Hydrochloric Acid SCHEMBL5006205 0.69 CYP2A6 (0.39) SMN1; SMN2CYP2A6HTR2ATAAR1LOXL2
Hydrochloric Acid SCHEMBL5006202 0.69 CYP2A6 (0.39) SMN1; SMN2CYP2A6HTR2ATAAR1LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7452893-B2 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists MERCK & CO., INC. (US) 2008-11-18 US disclosed
US-7452893-B2 4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists MERCK & CO., INC. (US) 2008-11-18 US disclosed
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients MERCK & CO., INC. (US) 2007-02-15 US disclosed
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients MERCK & CO., INC. (US) 2007-02-15 US disclosed
WO-2005019221-A1 4-CYCLOALKYLAMINOPYRAZOLO PYRIMIDINE NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037829-A1 e.g. trans-(4-Phenethyloxy-cyclohexyl)-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine; neurodegenerative disorders, analgesic, antidepressant, anxiolytic agent; Parkinson's disease, Alzheimer's disease, epilepsy, ischemic brain injury, stroke; with other active ingredients GRIN2B, GRIN3A, GRIN2A KEAP1 1028/4885ALDH1A1 636/4885FFAR1 1135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.